AXN – As mentioned in the recent Aoxing Pharmaceutical blog, I ended my position in this stock as the company announced a delisting of their common stock. The remaining proceeds have been reinvested into 22nd Century Group and TransEnterix Inc.
OBCI – Continuing to hold steady in this growth stock as it tracks towards $6. Key notables include expansion of manufacturing facility, entry into the pet cleaning market, established trend of year over year sales growth, and the recent special dividend.
SIFY – I hope you were able to benefit from the recent uptrend as I have! I have recently exited my position to lock in a 140% gain. I am weighing the option of waiting for the dip and settle or opening a new position in another company, such as XGTI or NSPR.
XXII – Continuing to add here and there. I am still excited about the growth potential here and believe it is only a matter of time until management begins signing deals and generating substantial revenue.
NVAX – Continuing to hold my position here with no increases or decreases in position.
TRXC – Opened a recent position during the quarter here as signs from my research point to a potentially large commercial opportunity if the FDA grants their Senhance robotics system approval.
The end of the road has been reached for this company! And I have to say, it will not be missed. Today, AXN has announced a deregistration of their common stock and eventual delisting. The main reason for this action gravitating towards the company’s financial woes.
So, what are some takeaways? A lack of communication between a company and its shareholders is one point that I would bring to light with AXN. The inability to keep investors aware of company activities, at a point when relying on investors may have helped the financial situation, could have played a role in the continuing decline of the stock price. Another takeaway is the revolving door of the chief financial officer position. It seemed every couple of years or so, a new CFO took the helm only to resign a couple years later.
The company continues to have potential in China. For now that remains to be seen…
The Chinese Pharmaceutical landscape is chock full of companies. Many with cutting edge developments and growing revenues. In particular, the demand for pain management medication is growing as the culture is slowly transitioning from one rooted in traditional beliefs and herbal therapies to one of pills and operations. I’m attributing this trend to advancements in therapies and western influence. This brings me to Aoxing Pharmaceutical.